Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Polen Focus Growth Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q4 2024 investor letter: "We also added to our positions in Oracle, Zoetis, and Eli Lilly and ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

Parnassus Core Equity Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q4 2024 investor letter: “Eli Lilly and Company (NYSE:LLY)stock declined following worse-than ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

RiverPark Large Growth Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q4 2024 investor letter: "Eli Lilly and Company (NYSE:LLY): LLY was a top detractor in the fourth ...

Eli Lilly saw a notable 10% increase in its stock ... Additionally, positive earnings results for Q4 2024, with sales reaching $13.53 billion, played a key role, as did the European Medicines ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...